Sanofi produces more Lemtrada data ahead of second FDA approval decision
This article was originally published in Scrip
Executive Summary
Sanofi subsidiary Genzyme has released interim results from the second year of an extension study for multiple sclerosis drug Lemtrada (alemtuzmab), which show that relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug in Phase III trials.